Guava Technologies has announced its progress in the transition of customers from the Guava EasyCD4 system to the recently launched Guava AutoCD4 system.
The AutoCD4 system, based on the personal cell analysis (PCA) platform, is part of Guava's broader effort to develop easy to use and maintain technology designed to monitor treatment of HIV/AIDS.
The AutoCD4 system offers several advantages over its predecessor, including new automated gating and acquisition software and a single antibody cocktail.
The software allows operators with minimal technical expertise to monitor a patient's T-lymphocytes accurately.
Guava said the CD4 value is particularly critical for paediatric patients.
From this single assay, a technician can get a patient's CD4 count, total lymphocyte count, and CD4 per cent value with only 10ul of whole blood and acquire results with one click of a button.
The software also includes an error detection feature and easy-to-read results in the form of individual patient as well as summary reports.
